Axogen reported first-quarter 2026 revenue of $61.5 million, up 26.6% from $48.6 million a year earlier, as the company posted stronger margins and a sharp improvement in cash.
Gross margin widened to 75.2% from 71.9% in the prior-year quarter. Adjusted EBITDA rose to $5.7 million from $2.9 million, while adjusted net income improved to $4.1 million, or $0.07 per share, from an adjusted net loss of $0.9 million, or $0.02 per share.
The company’s bottom-line loss deepened on a reported basis, with net loss increasing to $19.6 million, or $0.38 per share, from $3.8 million, or $0.08 per share in the first quarter of 2025.
Cash and investments climbed to $103.6 million at March 31, 2026, up $58.1 million from $45.5 million at Dec. 31, 2025.
Management raised full-year 2026 revenue guidance to at least 20% growth, or $270 million, and said gross margin should land between 74% and 76%. The company also said it expects to be free cash flow positive for the full year.
Axogen said growth was broad-based across its markets, with double-digit gains in extremities, oral maxillofacial and head and neck, and breast. It also cited new positive coverage decisions from Cigna and Elevance Health, and said a new CMS Level 3 nerve procedure code boosted Avance facility reimbursement 40% year over year to $8,965 for hospital outpatient settings and 35% to $6,157 for ASC-based procedures.
On Jan. 23, the company completed an upsized public offering that brought in $133.3 million in net proceeds. It used $69.7 million of that cash to fully repay and terminate its Oberland loan facility on Jan. 28, leaving the rest for working capital, capital expenditures and general corporate purposes. Following these announcements, the company's shares moved 4.92%, and are now trading at a price of $39.25. For the full picture, make sure to review Axogen's 8-K report.
